Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

Advanced FiltersClear Advanced Filters
3  Enrolling
7  Total Trials
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lym...
Enrolling
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-322
Drugs: Pirtobrutinib, Rituximab, Venetoclax
Age
≥18 years
Phase
III
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Enrolling
Conditions: Mantle Cell Lymphoma
Trial Name
BRUIN-MCL-321
Drugs: Acalabrutinib, Ibrutinib, Pirtobrutinib, Zanubrutinib
Age
≥18 years
Phase
III
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Enrolling
Conditions: Chronic Lymphocytic Leukemia, B-cell Leukemias, Small Lymphocytic Lymphomas
Trial Name
BRUIN-CLL-314
Drugs: Pirtobrutinib, Ibrutinib
Age
≥18 years
Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
4 
Completed Enrollment
7  Total Trials
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small...
Completed Enrollment
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-321
Drugs: Bendamustine, Idelalisib, LOXO-305, Rituximab
Age
≥18 years
Phase
III
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Smal...
Completed Enrollment
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-313
Drugs: Bendamustine, Pirtobrutinib, Rituximab
Age
≥18 years
Phase
III
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Completed Enrollment
Conditions: Leukemia - AML, Leukemia - CML, Myelodysplastic Syndrome
Trial Name
I9Y-OX-JDHB
Drugs: LY3410738
Age
≥18 years
Phase
I
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Completed Enrollment
Conditions: Blood Cancers
Drugs: LOXO-338 / LY3847429, Pirtobruitinib
Age
≥18 years
Phase
I